Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort

Blood Cancer J. 2024 Sep 30;14(1):167. doi: 10.1038/s41408-024-01150-3.

¹ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark. mariem@rm.dk.
² Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. mariem@rm.dk.
³ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
⁴ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁵ Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark.
⁶ Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
⁷ Department of Hematology, Odense University Hospital, Odense, Denmark.
⁸ Department of Hematology, Region Hospital Gødstrup, Gødstrup, Denmark.
⁹ Department of Hematology, Lillebælt Hospital, Vejle, Denmark.
¹⁰ Department of Pathology, Copenhagen University Hospital, Copenhagen, Denmark.
¹¹ Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
¹² Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
¹³ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark. majlud@rm.dk.
¹⁴ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. majlud@rm.dk.

No abstract available

Publication types